Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection

Kappers, Ingrid; Sandick, Johanna W. van; Burgers, J. A.; Belderbos, J.; Wouters, Michel W. J. M.; Zandwijk, Nico van; Klomp, Houke M.

doi:10.1016/j.ejcts.2009.04.069

Cited by 37 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even long-term (5-year) survival rates resulted improved reaching 44% (SWOG 9416) and 56% (JCO 9806), respectively. Based on these data, the modern standard treatment for sulcus superior tumors has become the combination of induction CT/RT followed by radical surgical resection (25,29,(35)(36)(37)(38)(39)(40)(41)(42)(43) (Table 1).…”

Section: A B Cmentioning

confidence: 99%

“…Operative mortality rate ranges from 0% to 6.9% and morbidity from 11% to 47% (25,29,(35)(36)(37)(38)(39)(40)(41)(42)(43). In particular, the SWOG 9416 (35) and JCO 9806 (36) phase II trials showed operative mortality rates of 2.3% and 3% and morbidity rates of 52% and 14%, respectively.…”

Section: Complicationsmentioning

confidence: 99%

“…In patients treated with bimodality therapy local recurrences were 70% of all recorded relapses (43,63). The percentage reduced to less than 30% of all recurrences in patients treated with trimodality therapy (35)(36)40).…”

Section: Prognostic Factors and Relapsesmentioning

confidence: 99%

See 2 more Smart Citations

Superior sulcus tumors (Pancoast tumors)

et al. 2016

View full text Add to dashboard Cite

Section: A B Cmentioning

confidence: 99%

Section: Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Superior sulcus tumors (Pancoast tumors)

et al. 2016

View full text Add to dashboard Cite

“…Wyniki badań bez losowego doboru chorych wskazują, że zastosowanie przedoperacyjnej chemioterapii w skojarzeniu z napromienianiem jest uzasadnione w przypadku lokalizacji nowotworu w szczycie płuca (guz Pancoasta) [39][40][41]. We wcześniejszych badaniach w przedoperacyjnej radiochemioterapii stosowano dawki w granicach 45-50 Gy, ale nowsze doniesienia wskazują, że bezpiecznie można zastosować wyższą dawkę [40].…”

Section: Przedoperacyjna Chemioterapiaunclassified

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Jassem

Biernat

Bryl

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Rak płuca jest w Polsce najczęstszą przyczyną zgonów nowotworowych. Około 85% wszystkich nowotworów płuca stanowi rak niedrobnokomórkowy (NDRP), w którym leki cytotoksyczne i ukierunkowane molekularnie odgrywają coraz większą rolę. W pracy przedstawiono oparte na obecnej wiedzy zalecenia dotyczące stosowania tych metod w praktyce klinicznej u chorych na NDRP oraz na złośliwego międzybłoniaka opłucnej.

show abstract

“…En-bloc resection of the upper lobe, ribs, nerves (brachial plexus) plus or minus vessels is recommended. Many studies published in the past 10 years have established the gold standard in the field as induction therapy consisting of high dose radiotherapy with concurrent cisplatin-based chemotherapy, followed by surgery 4-6 weeks later [124][125][126][127][128][129]. Using this multimodality scheme, perioperative mortality is low and 5-year survival rates are now consistently .40%.…”

Section: Superior Sulcus Tumours (Pancoast Tumours)mentioning

confidence: 99%

Surgery for nonsmall cell lung cancer

Lang-Lazdunski

2013

European Respiratory Review

View full text Add to dashboard Cite

Surgery remains the best curative option in patients with early stage lung cancer (stage I and II). Developments in minimally invasive techniques now allow surgeons to perform lung resections on elderly patients, patients with poor pulmonary function or significant cardiopulmonary comorbidities. New techniques, such as stereotactic radiotherapy and ablative procedures, are being evaluated in early-stage lung cancer and may represent an alternative to surgery in patients unfit for lung resection. Perioperative mortality rates have dropped significantly at most institutions in the past two decades and complications are managed more efficiently. Progress in imaging and staging techniques have helped cut futile thoracotomy rates and offer patients the most adequate treatment options. Large randomised trials have helped clarify the role of neoadjuvant, induction and adjuvant chemotherapy, as well as radiotherapy. Surgery remains an essential step in the multimodality therapy of selected patients with advanced-stage lung cancer (stage III and IV). Interventional and endoscopic techniques have reduced the role of surgery in the diagnosis and staging of nonsmall cell lung cancer, but surgery remains an important tool in the palliation of advanced-stage lung cancer. Large national/international surgical databases have been developed and predictive risk-models for surgical mortality/morbidity published by learned surgical societies. Nonetheless, lung cancer overall survival rates remain deceptively low and it is hoped that early detection/screening, better understanding of tumour biology and development of biomarkers, and development of efficient targeted therapies will help improve the prognosis of lung cancer patients in the next decade. @ERSpublications Despite progress in surgical techniques, radiotherapy techniques and targeted therapy, lung cancer prognosis remains poor

show abstract

Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection

Cited by 37 publications

References 26 publications

Superior sulcus tumors (Pancoast tumors)

Superior sulcus tumors (Pancoast tumors)

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Surgery for nonsmall cell lung cancer

Contact Info

Product

Resources

About